Abstract：
Neuroendocrine prostate cancer (NEPC) is a histological variant of prostate cancer and is characterized by aggressiveness and poor clinical outcomes. NEPC usually develops as a mechanism of treatment resistance in patients receiving hormone therapy for advanced prostate cancer. NEPC is sensitive to primary platinum-based chemotherapy, and has a short response duration. Second-line therapy is required in many cases, but clinical data on subsequent treatment after progression to first-line chemotherapy is limited. Here we report our experience of four cases of NEPC treated with second-line chemotherapy. Progression-free and overall survival rates were very low in three of the patients. One patient received multidisciplinary therapy using systemic and local chemotherapy and radiation therapy and survived for 24 months after initiation of second-line chemotherapy. Multidisciplinary therapy with chemotherapy and radiation is a promising option for improving the survival of patients with NEPC.
摘要：
神经内分泌前列腺癌（NEPC）是前列腺癌的组织学变体，其特征在于侵袭性和不良的临床结果。NEPC通常发展为接受激素治疗的晚期前列腺癌患者的治疗抵抗机制。NEPC对原发性铂类化疗敏感，并且具有短的响应持续时间。在许多情况下需要二线治疗，但进展为一线化疗后后续治疗的临床数据有限.在这里，我们报告了4例NEPC接受二线化疗的经验。其中三名患者的无进展生存率和总生存率非常低。一名患者接受了使用全身和局部化疗和放疗的多学科治疗，在二线化疗开始后存活了24个月。化疗和放疗的多学科治疗是改善NEPC患者生存率的有希望的选择。
